<DOC>
	<DOCNO>NCT02293317</DOCNO>
	<brief_summary>This single-site , randomize , double-blind , placebo-controlled study Multimeric-001 thirty six ( 36 ) volunteer 50-65 year age . All subject receive intramuscular ( IM ) injection , one three visit , 21±2 day interval treatment .</brief_summary>
	<brief_title>Phase II Study Assess Safety &amp; Immunogenicity Multimeric-001 Influenza Vaccine , Followed TIV</brief_title>
	<detailed_description>Subjects undergo screen procedure within 30 day prior first vaccination include medical history , vital sign , ECG , physical examination safety blood urine lab test . On first treatment visit , eligible subject undergo pre-dose physical examination vital sign , blood sample drawn baseline cellular immunogenicity circulate Interferon gamma ( IFN-g ) . They receive IM injection either vaccine placebo , accord treatment assignment , deltoid muscle preferably arm . The subject remain medical supervision 2 hr ( ± 15 min ) time release Clinical research center . The second treatment take place 21 ( ±2 ) day first vaccination . Procedures Visit 2 Additional two follow-up visit take place approximately 24 hr 48h The third treatment take place 21 ( ±2 ) day second vaccination . Procedures Visit 2 21 day later , subject immunize seasonal influenza vaccine approve 2014/15 year . A Study Termination visit take place 21 ( ±2 ) day last vaccination . Adverse event ( AEs ) change concomitant medication record , vital sign measure subject undergo physical examination ECG . Blood urine sample collect safety .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females ≥50 ≤65 year old time expect first injection . 2 . Eligible receive standard seasonal influenza vaccine accord ministry health guideline . 3 . Subjects provide write informed consent participate study . 4 . Subjects able adhere visit schedule protocol requirement available complete study . 5 . Premenopausal female subject must negative serum pregnancy test screen willing able use medically acceptable method birth control declare abstain sexual intercourse , screen visit study termination visit surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . 6 . Postmenopausal woman , define woman menstruation cessation 12 consecutive month prior sign inform consent form . 7 . Subjects must agree use acceptable contraceptive method full term study period ( include follow ) . 1 . Subjects likely , opinion investigator , confound result study may expose additional risk participation study , base medical history , vital sign , ECG , physical examination safety lab test . 2 . Subjects know Guillain Barré Syndrome past . 3 . Subjects immunized antiinfluenza vaccine infect influenza virus ( base assessment investigator ) within eight month prior first vaccination . 4 . Known hypersensitivity associate previous influenza vaccination . 5 . Use influenza antiviral medication within 4 week first vaccination . 6 . Known allergy egg protein 7 . Known hypersensitivity and/or allergy drug vaccine . 8 . Persons deficient produce antibody , whether due genetic defect , immunodeficiency disease , immunosuppressive therapy . 9 . History bleed disorder subject thrombocytopenia ( since bleeding may occur follow intramuscular administration subject ) . 10 . Positive serology Human immunodeficiency virus ( HIV ) , Hepatitis C Virus ( HCV ) antibody HBsAg . 11 . Any acute medical situation ( e.g . acute infection , ongoing flu symptom ) without fever within 48 hour vaccination , consider significant Investigator . 12 . Pregnant currently lactate woman . 13 . Subjects participate another interventional clinical study within 30 day prior first dose . 14 . Subjects noncooperative unwilling sign consent form .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Influenza Prime universal vaccine M-001 Multimeric</keyword>
</DOC>